reason report
better time around valid platform poc come
bottom line initi coverag aptinyx aptx
outperform rate price target aptinyx clinic
stage biotechnolog compani focus develop novel synthet
small molecul target n-methyl-d-aspart nmda receptor
signal pathway therapeut applic common neurolog
diseas diabet neuropath pain fibromyalgia wide
recogn novel nmda target agent could benefici mani
diseas provid avoid typic safeti toler liabil
gener associ drug class ketamin
aptinyx medicin differ exist nmda drug exert
modulatori effect bidirect activ rather full antagonist
activ multipl nmda receptor subtyp
differ basi differenti efficaci toler
aptinyx drug allergan acquisit naurex on-going research
collabor aptinyx former naurex discoveri platform provid
valid aptinyx platform progress ex-naurex
drug rapastinel phase ii phase major depress disord
aptinyx retain full develop commerci right lead
compound well medicin pipelin
target nmda except applic psychiatri
dementia believ could address multi-billion dollar
commerci market pain diabet peripher neuropathi dpn
fibromyalgia fm on-going phase ii subsequ phase trial
success posit view commerci potenti
base histor success lyrica cymbalta
indic research suggest
great opportun need novel central act medicin treat
aptinyx manag team larg compos carryov
naurex experi develop clinic medicin
advanc proof concept poc pivot trial
success sold central nervou system compani
larg biopharmaceut compani previous histor
challeng area drug develop mark averag
failur rate stage clinic develop howev compani
success mid-lat stage trial readout space gener
signific return investor past month
believ aptinyx stock offer upsid multipl
proof concept trial potenti program
advanc phase ii phase well emerg
molecul platform next month assign
compani inform leerink partner llc research
revenu mm ep
dcf wacc
lt growth rate
gener fulli dilut share
outstand use cash per share
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
probabl success dpn fm
assum drug could reach market current forecast
risk-adjust us sale five year post-launch
includ revenu either aptinyx earlier stage pipelin asset
model forecast cash flow modest termin
valu contribut compani drug discoveri platform price
target base dcf repres upsid
recent close price
tabl content
invest thesi valuat risk
pathway neuropath pain
pain dpn larg commerci opportun
aptinyx creat spin-out drug discoveri platform naurex acquir allergan incept
robust technolog drug discoveri platform neuropsychiatr disord platform alreadi
valid progress one compound phase partner allergan rapastinel one phase ii aptinyx nyx-
compani view like prove capabl produc multipl molecul platform design
differ indic compani advanc program current phase ii trial pain diabet
peripher neuropathi fibromyalgia earlier program focus diseas relat
alter learning/memori cognit believ could address multi-billion dollar market dpn fm base
histor result lyrica pregabalin cymbalta duloxetin similar indic forecast probabl success
adjust revenu five year product launch current exclud indic
molecul cash flow forecast multipl proof concept phase ii readout offer attract near mid-term
catalyst investor success could result signific upsid stock
price target base discount cash flow dcf analysi current expect patent
expiri dcf valuat account cash flow current net cash use
wacc termin growth rate assign probabl approv dpn fm assum
drug launch reach risk-adjust us sale assum aptinyx engag
larger pharmaceut partner ex-u commerci exchang royalti reach mid-teen also model
signific share dilut time commerci launch expect compani requir
substanti addit equiti financ develop commerci larg indic
risk invest gener consist risk associ clinic stage biopharmaceut compani specif
risk clinic trial failur lack regulatori approv unforeseen safeti liabil lack drug effect appli aptinyx
compani similar stage develop addit risk specif aptinyx includ potenti
compani may never achiev product revenu posit cash flow futur period also realiz risk
compani nmda modul platform may ultim prove safe effect futur human clinic studi
end
clinic stage biotech compani develop novel nmda modul agent diseas
ration design synthet small molecul base mimick specif monoclon antibodi fab
focu treatment chronic neuropath pain addict neurodegen disord via valid
establish blockbust product valid opportun lyrica cymbalta high remain unmet need
favor social demograph trend opioid crisi diabet incid age popul
naurex sale allergan relationship provid platform valid
allergan purchas naurex spun platform earli pipelin aptinyx
lead naurex compound rapastinel phase valid aptinyx platform posit ph ii major
research collabor allergan continu certain call option restrict aptinyx
experienc well regard manag team board
manag team compos primarili prior naurex team
board director includ notabl healthcar investor bain new adam street
view aptinyx attract invest space
nmda valid druggabl target brain clear opportun
experienc manag team drug develop expertis larg
allergan research collabor posit phase ii data rapastinel
chronic neuropath diseas diabet neuropathi fibromyalgia
high remain unmet need despit multipl approv medicin
verifi feedback medacorp kol
opportun get ahead multipl proof-of-concept readout
phase ii pain diabet neuropathi fibromyalgia studi top-lin result
aptinyx born naurex drug discoveri engin
newli form aptinyx retain develop right candid research -phase -phase -indallergan acquir naurex million up-front cashglob right rapastinel oral follow-on naurex discoveri platformallergan retain opt-in licens right drug candid rapastinel advanc phase trial posit phase ii data mdd develop -phase -phase itwo select remain aptinyx inc
aptinyx molecul come chemistri naurex drug
naurex initi found base proprietari peptid chemistri platform enabl develop ration design
molecul deriv hypervari region monoclon antibodi
hypervari region form antigen bind site give antibodi specif
aptinyx platform consist synthet small molecul develop naurex peptid chemistri
aptinyx gener novel platform rapastinel mimet use novel chemic synthesi approach known
spirocycl beta lactam chemistri first describ chemist bittermann gmeiner
chemistri use aptinyx allow product oral bioavail small molecul similar select
potenc peptid precursor
aptinyx three nmda modul pipelin
multipl proof-of-concept data readout come
phase ii data
phase ii data
phase ii data
phase data
aptinyx season manag led naurex leadership
former presid ceo naurex prior allergan acquisit
previous held manag level role baxter hoechst marion roussel sanofi
serv board director aptinyx previous
previous vice presid drug develop naurex
previous held ceo role pharmakey senior level posit merck sanofi scynexi
previous vice-president corpor develop naurex
serv director busi develop prior naurex also work consult
palladium group ernst young
previous svp strategi busi develop baxter year
work boston consult group hold medic degre univers oxford
join naurex vice presid prior allergan acquisit
serv sever role lundbeck prior join naurex includ chief medic offic vice-president us drug develop
found naurex serv cso prior allergan acquisit
distinguish professor biomed engin northwestern univers
regard research nmda receptor pathway
attract risk/reward balanc highlight manag platform valid
histor drug develop
prone failur
enter market gener competit
payer may requir step-through decid
cover brand drug
rapastinel royalti mileston fall back
discontinu rapastinel oral follow-on
valid manag team drug discoveri enginemultipl proof concept readout next monthsnovel oral medicin area high unmet needrapastinel phase ii success de-risk platformpotenti multipl addit drug candid address diseasesposit aptinyx inc
pathway neuropath
pain neuropathi caus either peripher central nervou
either peripher
central mediat result
process over-
sensit alter
transmiss inhibit
ideal treatment neuropath pain
pathway peripher
aim normal central pathway lead hyper-sensit
abnorm
current standard care
drug classexamplesmain pathwayefficaci neuropath pain associ liabilitiesgabapentinoidspregabalin lyrica gabapentinperipher central mediat inhibitionmoder efficacysed dizzy habituationsnrisduloxetin cymbalta central mediat transmissionmoder efficaci comorbid depressionweight gain dri mouth fatigu drug interactionstcascyclobenzaprin amitriptylinecentr mediat transmissionmoder efficaci comorbid depressionsimilar snrisnmdaketamin memantinecentr sensitizationlimit efficacyhallucin disorientationopioidsmorphin oxycodoneperipher central mediat inhibitionlimit efficacysed habituationtopicalslidocain capsaicinperipher ion channelslimit efficacyinconveni dosing/administrationna channel blockersdrug develop ion channelsunknownunknown aptinyx inc
medacorp kol highlight unmet need novel central act medicin
neuropath pain like mix peripher central abnorm major case
optim treatment neuropath pain would includ combin peripher central act agent
medacorp kol feedback highlight need novel central act medicin safe well
toler current use centrally-act medicin numer liabil well limit efficaci
liabil associ alter sensit pathway includ hallucin disorient
liabil associ pathway alter excitability/inhibit includ sedat dizzi
liabil associ alter neuron transmiss includ mood abnorm
target nmda modul central process pain sensit
nmda main excitatori receptor brain
primari excitatori neurotransmitt central nervou system glutam gaba major inhibitori
glutam bind sever differ receptor exert effect includ nmda ampa kainat receptor
nmda primari glutam receptor act via ion-channel mechan result increas intracellular
calcium glutam bound
activ nmda receptor glutam result
channel open allow calcium ion enter
cell trigger cascad signal
lead long-term potenti ltp
ltp strengthen signal neural cell
import compon learn
multipl nmda receptor subtyp exist bind
site accommod one type
numer neurolog psychiatr indic
could target via pathway
market drug ketamin memantin
namenda amantadin gocovri target
purv et al neurosci dore et al journal neurosci file
nmda antagonist describ histori liabil limit
kol highlight
strong desir find
novel form ketamin
aptinyx molecul bind novel distinct
partial agonist
antagonist well
agonist
antagonist activ
receptor
aptinyx lead compound design avoid liabil ketamin
thought modulatori effect
nmda vs antagonist ketamin
potenti higher concentr inhibit nmda
activ
degre inhibit limit vs ketamin
addict potenti
mice treat becam resist neuropath pain
symptom follow dose
appear stronger effect gabapentin
mice treat appear higher pain threshold
treatment versu vehicl control
model effect similar gabapentin
establish model mice evalu abus potenti show
effect
proport mice self-administ drug show rapid toler
habitu ketamin
proport mice show toler indistinguish
human data show wide adequ csf exposur
singl multipl ascend dose healthi
exposur minim accumul
hour dose rapid onset half-lif hour
abl achiev cerebr spinal fluid csf
concentr plasma concentr
subject treat dose oral
treatment relat advers event occur
subject abdomin distent flatul
well toler therapeut index
estim
studi phase ii trial
diabet peripher neuropathi fibromyalgia
houck et al american societi experiment neurotherapeut meet poster
onset anti-depress
drug relat
toler patient
phase major depress
disord on-going
onset activ nmda
given safe wide
progress phase ii phase
naurex allergan compani press releas leerink research
pain diabet peripher neuropathi secondari manifest
pain diabet peripher neuropathi thought occur diabet patient
estim million individu us
symptom late manifest diabet tend progress hyperglycemia worsen
hyperalgesia increas sensit burn pain paresthesia abnorm sensat numb occur
lower leg hand tend first bodi part affect
stock glove pattern
symptom progress increas length sever underli diseas
dpn secondari manifest diabet analog diabet nephropathi gastroparesi retinopathi
dpn chronic progress diseas revers better glycem control
manag dpn associ frequent switch off-label use
medicin
cymbalta
switch
capsaicin
off-label use
common
like
efficaci lyrica cymbalta leav room improv
current line medicin provid pain relief patient
medacorp kol feedback suggest patient get meaning pain relief less remain
treatment beyond year
benefit gabapentin tca thought similar
opioid also shown similar benefit approv medicin number random control trial
howev effect tend wane chronic administr among liabil
drugproport pain reduct pbo adjust proport pain reduct pbo adjust pregabalin aptinyx inc
phase ii studi current enrol dpn
phase ii enrol subject pain dpn receiv either placebo day primari endpoint
chang baselin numer rate scale nr pain intens week
accord clinicaltri gov phase ii began recruit june complet enrol end
aptinyx expect report top-lin data studi
conserv estim suggest sale potenti us market alon
assum us launch dpn
current assum payer requir step-through either gener lyrica gener cymbalta
estim list price slight discount list price brand lyrica
current use probabl success base stage develop ph ii
pain diabet peripher neuropathi diabet popul pain diabet pain diabet diagnos seek diagnos seek treatment treat revenu us- probabl success adjust revenu us- aptinyx inc
fibromyalgia trial
believ million fibromyalgia patient us seek pain relief
fibromyalgia character chronic gener musculoskelet pain fatigu
upper lower bodi soft tissu tender fatigu cognit disturb frequent report
comorbid depress
unclear etiolog high concord psychiatr symptom complic diagnosi treatment
lack physic abnorm peripher nerv lesion strengthen argument fibromyalgia product
central sensit
estim preval adult popul higher preval women
estim million diagnos patient us seek treatment fibromyalgia-rel pain
current treatment involv cognitive/behavior psycholog pharmacolog intervent
drug target central mediat pain pathway use similar dpn
cymbalta
fda
influenc
treat
switch
capsaicin
select serotonin reuptak inhibitor ssri patient comorbid depress popul
treatment landscap notabl modest efficaci frequent switch
current line medicin provid meaning pain relief small proport patient
medacorp kol combin medic literatur suggest less patient meaning
symptom improv current line option
modest efficaci toler issu result short durat treatment frequent switch
larg meta-analys indic half subject unabl titrat optim dose
remain treatment beyond one year
medacorp feedback suggest novel agent could approv modest effect size
drugproport pain reduct pbo adjust proport pain reduct pbo adjust tca amitriptylin aptinyx inc
phase ii trial current enrol fibromyalgia
exploratori phase ii studi fibromyalgia enrol subject moderate-sever fibromyalgia two us
locat primari object chang neuroimag biomark function mri six week
top-lin data posit result would establish proof-of-concept provid foundat pivot phase
assum launch one year dpn
current phase ii program exploratori studi subject
underdiagnosi prevent fibromyalgia larg commerci indic dpn
assum subject comorbid depress preferenti use medicin anti-depress activ
fibromyalgia fibromyalgia popul diagnos seek diagnos seek treatment treat revenu probabl success adjust revenu us- aptinyx inc
gross revenu forecast risk-unadjust
actual report launch lyrica cymbalta
pain diabet neuropathi fibromyalgia repres larg popul demograph tailwind
increas treatabl pool increas incid diagnosi preval
assum list price discount current lyrica peak penetr elig
dollar long-term commerci opportun leerink estim us market alon
proof concept indic anticip
phase ii data
phase ii data
follow-on nmda modul studi ptsd
oral avail nmda receptor modul differenti bind profil within nmda receptor domain
grant track design fda treatment post-traumat stress disord ptsd
on-going phase studi ptsd phase ii initi plan
toler date subject experienc advers event deem studi drug relat
pharmacokinet profil look similar singl multipl ascend dose
ptsd market well establish due lack specif treatment option us dept veteran affair va
estim lifetim preval ptsd point preval
equat potenti market size million diagnos individu base assumpt
veteran constitut easili identifi market high preval
ptsd gener treat anti-depress drug ssri snri new drug approv
indic year
product candid expect enter phase futur develop parkinson diseas
mechanist rational therapeut use parkinson diseas base anim model demonstr
cognit dysfunct relat nmda dysregul impair synapt plastic
nation institut nih estim individu parkinson us
individu either mild cognit impair parkinson dementia
potenti backbon parkinson treatment address underli cognit dysfunct
on/off label use cholinesteras inhibitor rivastigmin donepezil aricept nmda
antagonist memantin namenda establish multi-billion dollar market treat parkinson
medicin avail gener formul substanti side effect efficaci limit
complet phase safeti pk studi expect
earli trial data also expect
data earli program come
includ either revenu forecast valuat progress poc trial
robust proof-of-concept result could provid broader platform valid
increas confid
phase ii data
phase data
mani nmda direct molecul activ clinic develop almost
developerdrugmechanismindicationsdevelop stageadamasgocovri amantadin nmda antagonist dopamin reuptak inhibitorparkinson dyskinesia approv multipl antagonistrett syndromephas select nmda antagonistmajor depress disorderphas iiimmun topic nmda antagonist serotonin norepinephrin reuptak inhibitorpost-herpet neuralgiaphas iijnjesketaminenmda antagonistmajor depress disorderphas iiiimmun topic nmda antagonist serotonin norepinephrin reuptak inhibitorpost-herpet neuralgiaphas iineurorxcycluradantagonist nmda dopamin serotonin receptorsbipolar disorderphas posit alloster modulatorunannouncedphas select nmda antagonistepilepsyphas antagonistmajor depress disord neuropath painphas ii aptinyx inc
neuropath pain also attract mani novel develop program
developerdrugmechanismdevelop stage np pain icara associ kinasephas ii receptorphas iisumitomo antagonistphas aptinyx inc
allergan retain sever draft pick aptinyx molecul aptinyx
signific restrict develop
follow allergan purchas naurex up-front max total valu earli stage
pipelin technolog platform spun back independ biotech compani aptinyx capit
multipl privat round total led notabl healthcar investor
allergan retain access aptinyx discoveri platform secur valu rapastinel relev successor
aptinyx allergan on-going research collabor two compani altern select
right new compound aptinyx platform enter investig new drug ind enabl studi
select compani assum development respons program
allergan pay million exercis fee select three compound max within five-year period
select compound unencumb either direct royalti oblig either direct
allergan field indic limit psychiatr disord ptsd addict development
disord alzheimers-rel diseas
field exclus avail aptinyx aptinyx unabl develop molecul indic
estim could launch us
leerink aptx revenu forecast sale po diabet neuropathi us fibromyalgia us total us po adjusted- diabet neuropathi ex-u sale book partner fibromyalgia ex-u sale book partner total ex-u po adjust book partner total ex-u po adjust royalti aptx collab product sale collab aptinyx inc
believ aptx could break even
leerink aptx incom statement model sale collab po adjust post-launch incom incom interest incom incl nol forma earn exclud option expens net per share per share dilut exclud option ave share weight ave share aptinyx inc
price base discount flow
includ dilut financ
aptx dcf flow termin equiti share outstand valu per growth aptinyx inc
companysageitcibhvnaciumeanaptxdevelopment stage ipophas iicomplet phase iicomplet phase iiphas iiiphas iilead indicationsup refractori statu epilepticusschizophreniaacut migrainealzheim diseasepain neuropathymarket cap post-ipo enterpris valu post-ipo cap trade rang follow current trade rang aptinyx inc
lp balanc sheet statement
leerink aptx select balanc sheet flow item sheet dataoper asset cash plant equip oper oper oper asset asset stockhold liabil sharehold dataoper snet incom asset scapit market sproce public offer chang capit stock chang begin end oper oper adjust tax op incom tax increas work capit acquisit licens aptinyx inc
